Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS INDUCED BY NON-ALCOHOLIC STEATOHEPATITIS, CONTAINING, AS ACTIVE INGREDIENT, EXPRESSION INHIBITOR OF LIPOCALIN 2 OR RECEPTOR THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/140664
Kind Code:
A1
Abstract:
The present invention relates to: a pharmaceutical composition for preventing or treating liver fibrosis induced by non-alcoholic steatohepatitis, containing, as an active ingredient, an expression inhibitor of lipocalin 2 or a receptor thereof; a method for inhibiting the activation of hepatic stellate cells by treatment with the lipocalin 2 receptor inhibitor; and a method for screening for agents for non-alcoholic steatohepatitis-induced liver fibrosis diagnosis and liver fibrosis treatment by using lipocalin 2. The composition containing, as an active ingredient, a lipocalin 2 receptor inhibitor or a lipocalin 2 expression inhibitor, of the present invention, can be used as a therapeutic agent for non-alcoholic steatohepatitis-induced liver fibrosis. The present invention can provide a method for screening for agents for non-alcoholic steatohepatitis-induced liver fibrosis diagnosis and liver fibrosis treatment by using lipocalin 2, and can provide a method for inhibiting the activation of hepatic stellate cells by treatment with a lipocalin 2 receptor inhibitor.
More Like This:
Inventors:
ROH GU SEOB (KR)
KIM KYUNG EUN (KR)
LEE JAEWOONG (KR)
KIM KYUNG EUN (KR)
LEE JAEWOONG (KR)
Application Number:
PCT/KR2023/000979
Publication Date:
July 27, 2023
Filing Date:
January 19, 2023
Export Citation:
Assignee:
NAT UNIV GYEONGSANG IACF (KR)
International Classes:
A61K48/00; A61K31/713; A61P1/16; A61P43/00; C12Q1/6883; G01N33/50; G01N33/53; G01N33/68
Foreign References:
| KR101575093B1 | 2015-12-08 |
Other References:
KRIZANAC MARINELA, MASS SANCHEZ PAOLA BERENICE, WEISKIRCHEN RALF, ASIMAKOPOULOS ANASTASIA: "A Scoping Review on Lipocalin-2 and Its Role in Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 6, pages 2865, XP093079155, DOI: 10.3390/ijms22062865
XU GANG, WANG YU-MIN, YING MIAO-MIAO, CHEN SUI-DAN, LI ZONG-RUI, MA HONG-LEI, ZHENG MING-HUA, WU JIAN, DING CHUNMING: "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", CLINICAL AND MOLECULAR HEPATOLOGY, KOREAN ASSOCIATION FOR THE STUDY OF THE LIVER, KOREA, vol. 27, no. 2, 1 April 2021 (2021-04-01), Korea , pages 329 - 345, XP093079156, ISSN: 2287-2728, DOI: 10.3350/cmh.2020.0261
CHEN JIEGEN, ARGEMI JOSEPMARIA, ODENA GEMMA, XU MING-JIANG, CAI YAN, MASSEY VERONICA, PARRISH AUSTIN, VADIGEPALLI RAJANIKANTH, ALT: "Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), XP055874089, DOI: 10.1038/s41598-020-72172-7
TAN TAN, SONG ZHIYUAN, WANG RUNMING, JIANG SHUHENG, LIANG ZUOXIANG, WANG QI, HU XIAOXIANG, LI NING, XING YIMING: "Modelling Porcine NAFLD by Deletion of Leptin and defining the role of AMPK in hepatic fibrosis", BIORXIV, 7 June 2021 (2021-06-07), XP093079158, [retrieved on 20230906], DOI: 10.1101/2021.06.07.447327
KIM KYUNG EUN, LEE JAEWOONG, SHIN HYUN JOO, JEONG EUN AE, JANG HYE MIN, AHN YU JEONG, AN HYEONG SEOK, LEE JONG YOUL, SHIN MEONG CH: "Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 77, no. 3, 1 March 2023 (2023-03-01), US , pages 888 - 901, XP093079160, ISSN: 0270-9139, DOI: 10.1002/hep.32569
XU GANG, WANG YU-MIN, YING MIAO-MIAO, CHEN SUI-DAN, LI ZONG-RUI, MA HONG-LEI, ZHENG MING-HUA, WU JIAN, DING CHUNMING: "Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis", CLINICAL AND MOLECULAR HEPATOLOGY, KOREAN ASSOCIATION FOR THE STUDY OF THE LIVER, KOREA, vol. 27, no. 2, 1 April 2021 (2021-04-01), Korea , pages 329 - 345, XP093079156, ISSN: 2287-2728, DOI: 10.3350/cmh.2020.0261
CHEN JIEGEN, ARGEMI JOSEPMARIA, ODENA GEMMA, XU MING-JIANG, CAI YAN, MASSEY VERONICA, PARRISH AUSTIN, VADIGEPALLI RAJANIKANTH, ALT: "Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension", SCIENTIFIC REPORTS, vol. 10, no. 1, 1 December 2020 (2020-12-01), XP055874089, DOI: 10.1038/s41598-020-72172-7
TAN TAN, SONG ZHIYUAN, WANG RUNMING, JIANG SHUHENG, LIANG ZUOXIANG, WANG QI, HU XIAOXIANG, LI NING, XING YIMING: "Modelling Porcine NAFLD by Deletion of Leptin and defining the role of AMPK in hepatic fibrosis", BIORXIV, 7 June 2021 (2021-06-07), XP093079158, [retrieved on 20230906], DOI: 10.1101/2021.06.07.447327
KIM KYUNG EUN, LEE JAEWOONG, SHIN HYUN JOO, JEONG EUN AE, JANG HYE MIN, AHN YU JEONG, AN HYEONG SEOK, LEE JONG YOUL, SHIN MEONG CH: "Lipocalin‐2 activates hepatic stellate cells and promotes nonalcoholic steatohepatitis in high‐fat diet–fed Ob/Ob mice", HEPATOLOGY, JOHN WILEY & SONS, INC., US, vol. 77, no. 3, 1 March 2023 (2023-03-01), US , pages 888 - 901, XP093079160, ISSN: 0270-9139, DOI: 10.1002/hep.32569
Attorney, Agent or Firm:
CHOI, Kyu Whan (KR)
Download PDF: